Therefore, this suggested that the IDH1 mutant status may not be an ideal biomarker for predicting the survival of GBM patients due to the already existing high percentage of IDH1 wild-type within primary GBMs, although the IDH1 mutant status has been the most well-known prognostic and predicting biomarker for patients with lower grade gliomas. Here, IDH1 is linked to central nervous system cancer.